2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Breast Neoplasms
138
Neoplasms
118
Prostatic Neoplasms
64
Lung Neoplasms
48
Head and Neck Neoplasms
46
Colorectal Neoplasms
38
Ovarian Neoplasms
33
Uterine Cervical Neoplasms
29
Endometrial Neoplasms
23
Motor Activity
22
Neoplasm Metastasis
20
Multiple Myeloma
20
Pancreatic Neoplasms
19
Brain Neoplasms
19
Rectal Neoplasms
18
Lymphoma
17
Colonic Neoplasms
17
Pain
16
Gastrointestinal Neoplasms
16
Fatigue
16
Carcinoma, Non-Small-Cell Lung
16
Leukemia
15
Depression
15
Oropharyngeal Neoplasms
13
Melanoma
13
Anxiety Disorders
13
Urinary Bladder Neoplasms
12
Hematologic Neoplasms
12
Esophageal Neoplasms
12
Stomach Neoplasms
11
Interventions
pembrolizumab
7
lenvatinib
3
apatinib
3
Magnetic Resonance Spectroscopy
3
Imatinib Mesylate
3
Carboplatin
3
gallium 68 PSMA-11
2
Specimen Handling
2
Protons
2
Nivolumab
2
Epirubicin
2
Cisplatin
2
Axitinib
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tislelizumab
1
regorafenib
1
enfortumab vedotin
1
cabozantinib
1
avelumab
1
anlotinib
1
amivantamab
1
abemaciclib
1
Tretinoin
1
Trastuzumab
1
Tablets
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Sunitinib
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Adenoid Cystic
×
Surveys and Questionnaires
×
Clear all
NCT06535997
2025-08-06
PRIMHADRON
Hospices Civils de Lyon
Completed
62 enrolled